Abstract：Objective: To analyze the correlation between levels of peripheral blood neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and interleukin-17 (IL-17) and survival prognosis in patients with breast cancer. Methods: 120 patients with breast cancer who were treated in the hospital between January 2018 and February 2019 were selected as the research subjects and were included in the breast cancer group, and 106 subjects who underwent breast health examination in the hospital during the same period were selected as healthy controls. The levels of NLR, LMR and IL-17 in peripheral blood were compared between the breast cancer group and the healthy control group at enrollment. The relationship between levels of NLR, LMR and IL-17 and clinicopathological parameters of patients with breast cancer at enrollment was analyzed. The patients in the breast cancer group were followed up at discharge, and the prognosis was statistically analyzed and the predictive value of levels of peripheral blood NLR, LMR and IL-17 on the poor prognosis was analyzed. Results: The levels of NLR and IL-17 in peripheral blood of patients in the breast cancer group were significantly higher than those in the healthy control group (P<0. 05) while the level of peripheral blood LMR was significantly lower than that in the healthy control group (P<0. 05). The levels of peripheral blood NLR. LMR and IL-17 were not related to age, disease type, tumor size, presence or absence of triple-negative breast cancer, ki67 level and assessment of target lesions (P>0. 05), but were related to TNM stage (P<0. 05). The levels of NLR and IL-17 in peripheral blood in the poor prognosis group were significantly higher than those in the good prognosis group (P<0. 05) while the LMR level was significantly lower than that in the good prognosis group (P<0. 05). ROC curve results showed that the combined diagnosis of peripheral blood NLR+LMR+IL-17 had higher predictive efficiency than each indicator alone for poor prognosis of breast cancer, and the predictive value of LMR for poor prognosis of breast cancer had certain limitations (AUC=0. 652). Conclusion: The levels of NLR, LMR and IL-17 in peripheral blood of patients with breast cancer have certain reference value on evaluation of prognosis of patients.
齐晶, 李瑞娟, 史博慧. 乳腺癌患者外周血NLR LMR IL-17水平与预后的相关性研究[J]. 河北医学, 2022, 28(12): 2095-2099.
QI Jing, et al. Correlation between Levels of Peripheral Blood NLR LMR and IL-17 and Prognosis in Patients with Breast Cancer. HeBei Med, 2022, 28(12): 2095-2099.
[1] Burstein HJ,Curigliano G,Thürlimann B,et al.Customizing local and systemic therapies for women with early breast cancer:the St.Gallen international consensus guidelines for treatment of early breast cancer 2021[J].Ann Oncol,2021,32(10):1216-1235. [2] Trayes KP,Cokenakes SEH.Breast cancer treatment[J].Am Fam Physician,2021,104(2):171-178. [3] Offi C,Romano RM,Cangiano A,et al.Evaluation of LMR,NLR and PLR as predictors of malignancy in indeterminate thyroid nodules[J].Acta Otorhinolaryngol Ital,2021,41(6):530-536. [4] 刘军玲,周革,郭宏斌.IL-6联合NLR对三阴性乳腺癌术后患者预后的预测价值[J].中国医药导报,2020,17(8):113-116. [5] Dundr P,Gregova M,Bart M,et al.Review of tumor infiltrating lymphocytes assessment in breast cancer in routine diagnostic practice[J].Cesk Patol,2021,57(3):161-166. [6] 张媚粼,王梦晗,郑昂,等.术前NLR-PLR评分对乳腺癌患者预后的影响及相关因素分析[J].局解手术学杂志,2021,30(5):390-394. [7] 李华琼,张成,范雪娇,等.术前外周血NLR在乳腺癌患者预后评估中的价值分析[J].标记免疫分析与临床,2020,27(6):947-952. [8] Nicola S,Ridolfi I,Rolla G,et al.IL-17 promotes nitric oxide production in non-small-cell lung cancer[J].Clin Med,2021,10(19):4572. [9] 周琼,董杰,沈夏波.白介素-17在三阴性乳腺癌中的表达及其与新生血管和预后的相关性[J].肿瘤学杂志,2021,27(1):53-57. [10] 肖献秋,芮小平,王力,等.血清NLR和PLR与三阴性乳腺癌患者新辅助化疗效果的相关性分析[J].安徽医学,2021,42(7):795-798. [11] Tao L,Zhang L,Peng Y,et al.Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma:a new hypothesis and a new predictor for distant metastasis[J].Medicine (Baltimore),2016,95(39):e4932. [12] 孙莎莎,陈京龙,丁晓燕,等.中性粒细胞与淋巴细胞比值与肿瘤预后的研究进展[J].医学综述,2018,24(22):4469-4474.
2022, Vol. 28 
冀公网安备13080202000677号